STABILITY OF THE NEW ANTICANCER PLATINUM ANALOG 1,2-DIAMINOMETHYL-CYCLOBUTANE-PLATINUM(II)-LACTATE (LOBAPLATIN-D19466) IN INTRAVENOUS SOLUTIONS

被引:13
作者
GUCHELAAR, HJ
UGES, DRA
AULENBACHER, P
DEVRIES, EGE
MULDER, NH
机构
[1] UNIV HOSP GRONINGEN,DEPT PHARM,GRONINGEN,NETHERLANDS
[2] ASTA PHARMA,FRANKFURT,GERMANY
[3] UNIV HOSP GRONINGEN,DEPT MED ONCOL,GRONINGEN,NETHERLANDS
关键词
PLATINUM; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC); CISPLATIN ANALOG; D19466; LOBAPLATIN; 1,2-DIAMINOMETHYL-CYCLOBUTANE-PLATINUM(II)-LACTATE; DRUG STABILITY; SHELF LIFE;
D O I
10.1023/A:1015815908347
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The chemical stability of the new anticancer platinum analogue 1,2-diaminomethyl-cyclobutane-platinum(II)-lactate (D19466) in infusion media was studied in an accelerated stability testing experiment with a selective HPLC-UV method. Variables were time, temperature, light, concentration, and infusion mixture. Mean reaction rate constants of decomposition were, respectively, 0.9555 *10(-2), 2.127 *10(-2), and 4.221 *10(-2) hr-1 at 37, 56, and 66-degrees-C at a concentration of 200 mg/L in normal saline. From the Arrhenius equation, shelf lives (5% loss) at 4, 22, 37, and 121-degrees-C were, respectively, calculated to be 41.6, 13.2, 5.7, and 0.15 hr. Mean reaction rate constant in 5% dextrose was 3.106 *10(-2) hr-1 (200 mg/L; 56-degrees-C) and differed from that in normal saline (P < 0.005). Mean reaction rate constant in Ringer lactate was 2.084 *10(-2) hr-1 (200 mg/L; 56-degrees-C) (P > 0.05). There was no influence of normal daylight on the rate of decomposition. It is recommended to prepare D19466 infusions in normal saline. Chemical stability is then maximal 12 hr at room temperature or 24 hr at 4-degrees-C. No protection against normal daylight is required. Sterilization by heat is not possible.
引用
收藏
页码:808 / 811
页数:4
相关论文
共 15 条
[1]  
ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35
[2]   STABILITY OF CISPLATIN, IPROPLATIN, CARBOPLATIN, AND TETRAPLATIN IN COMMONLY USED INTRAVENOUS SOLUTIONS [J].
CHEUNG, YW ;
CRADOCK, JC ;
VISHNUVAJJALA, BR ;
FLORA, KP .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1987, 44 (01) :124-130
[3]   CISPLATIN METABOLITES IN PLASMA, A STUDY OF THEIR PHARMACOKINETICS AND IMPORTANCE IN THE NEPHROTOXIC AND ANTITUMOUR ACTIVITY OF CISPLATIN [J].
DALEYYATES, PT ;
MCBRIEN, DCH .
BIOCHEMICAL PHARMACOLOGY, 1984, 33 (19) :3063-3070
[4]  
GIETEMA JA, 1991, P ASCO HOUSTON, P100
[5]   STABILITY OF CISPLATIN IN AQUEOUS-SOLUTION [J].
GREENE, RF ;
CHATTERJI, DC ;
HIRANAKA, PK ;
GALLELLI, JF .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1979, 36 (01) :38-43
[6]  
GRIMM W, 1980, STABILITATSPRUFUNG P
[7]  
Hincal A A, 1979, J Parenter Drug Assoc, V33, P107
[8]  
HYDER PC, 1984, PLATINUM COORDINATIO, P213
[9]   DRUGS 5 YEARS LATER - CISPLATIN [J].
LOEHRER, PJ ;
EINHORN, LH .
ANNALS OF INTERNAL MEDICINE, 1984, 100 (05) :704-713
[10]  
MARIANI EP, 1980, CISPLATIN CURRENT ST, P305